Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Boehringer Ingelheim Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (8)
ARTG (5)
Australian public assessment report (AusPar) (3)

Date

(-) 2016 (14)
(-) 2007 (2)
2025 (6)
2024 (5)
2023 (8)
2022 (3)
2021 (6)
2020 (14)
2019 (2)
2018 (15)
2017 (4)
2015 (13)
2014 (4)
2013 (14)
2012 (3)
2011 (8)
2010 (5)
2008 (4)
2003 (1)
2002 (3)
2001 (4)
2000 (3)
1999 (7)
1998 (1)
1996 (1)
1993 (1)
1992 (1)
1991 (2)

Search

Filters applied:

2007
2016

Clear all

Sponsor content

16 result(s) found, displaying 1 to 10

GLYXAMBI 10 mg/5 mg empagliflozin/linagliptin 10mg/5mg film coated tablet blister pack (263556)

19 December 2016

ARTG

Australian Register of Therapeutic Goods (ARTG) information for GLYXAMBI 10 mg/5 mg empagliflozin/linagliptin 10mg/5mg film coated tablet blister pack.
GLYXAMBI 25 mg/5 mg empagliflozin/linagliptin 25mg/5mg film coated tablet blister pack (263557)

19 December 2016

ARTG

Australian Register of Therapeutic Goods (ARTG) information for GLYXAMBI 25 mg/5 mg empagliflozin/linagliptin 25mg/5mg film coated tablet blister pack.
PRAXBIND idarucizumab (rch) 50 mg/ml solution for injection/infusion vial (237761)

11 May 2016

ARTG

Australian Register of Therapeutic Goods (ARTG) information for PRAXBIND idarucizumab (rch) 50 mg/ml solution for injection/infusion vial.
RHINASPRAY tramazoline hydrochloride 1.18mg/mL nasal spray puffer pack Cancelled under s30(1)(c)

27 December 2016

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
DULCOLAX bisacodyl 5mg tablet blister pack (reformulation) Cancelled under s30(1)(c)

27 December 2016

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
BISOLVON DAY & NIGHT DRY pholcodine 1mg/mL oral liquid bottle Cancelled under s30(1)(c)

27 December 2016

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
BISOLVON CHESTY NATURAL KIDS ORAL LIQUID Cancelled under s30(1)(c)

27 December 2016

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
BEROMUN tasonermin (rbe) 1mg powder for injection vial_with diluent ampoule Cancelled under S30(1)

22 November 2016

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd
AusPAR: Idarucizumab

8 November 2016

Australian public assessment report (AusPar)

Australian Public Assessment Report for Idarucizumab
PRADAXA dabigatran etexilate 75 mg (as dabigatran etexilate mesilate) capsule bottle Cancelled under s30(1)

16 May 2016

Cancellation by sponsor

Requested by Boehringer Ingelheim Pty Ltd

Pages

Current page 1
Page 2
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.